HAMPTON, Va., November 14, 2018 – ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, announces a new international partner to manage distribution to support market expansion outside of the United States.

Following the CE marking of the ivWatch Model 400, the company signed an agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories, as its distributor for Australia and New Zealand.

“Our entry into these markets is a response to growing awareness and clinical demand,” said Scott Hensley, vice president of sales and business development at ivWatch. “We are now poised to meet the ongoing customer requests for our technology as they seek cutting-edge solutions to address the global problem of patient harm caused by peripheral IV infiltration.”

Upon completion of regulatory approval requirements for these markets, the ivWatch Model 400 system will be available for the new distributor to introduce clinicians to continuous monitoring to improve patient safety. The company has obtained ISO 13485:2016 Certification through the Medical Device Single Audit Program (MDSAP). MDSAP is a global standard for medical device quality management systems in which many international partners participate including the Therapeutic Goods Administration of Australia.

“Australia is home to vascular access leaders who are undertaking significant scientific research focused on combating IV therapy complications internationally,” said Paul Williams, director of New Medical. “We’re excited to put our technical teams in place to serve the needs of our customers. Our progressive health care market is equipped to make reliable early detection and notifications of this common IV complication a part of their efforts toward improving patient safety and outcomes.”

This week, ivWatch is attending MEDICA, the World Forum for Medicine, as part of their commitment to sharing their innovative technology with the global community. ivWatch will be a part of the U.S. Commercial Service’s Corporate Executive Office (CEO) Program located in Hall 16, C04 USA CEO Center.

To learn more about ivWatch and their industry partners, visit www.ivwatch.com/about-us/partnerships/.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLCwww.ivwatch.com

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Direct (757) 224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest